Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report), SAGE Therapeutics (SAGE – Research Report) and IQVIA Holdings (IQV – Research Report).
Gilead Sciences (GILD)
In a report issued on February 15, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences, with a price target of $101.00. The company’s shares closed last Friday at $71.58, close to its 52-week low of $71.37.
According to TipRanks.com, Syed is a 1-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $87.06, a 19.3% upside from current levels. In a report issued on February 16, Bank of America Securities also initiated coverage with a Buy rating on the stock with a $95.00 price target.
See today’s best-performing stocks on TipRanks >>
SAGE Therapeutics (SAGE)
Leerink Partners analyst Marc Goodman maintained a Hold rating on SAGE Therapeutics on February 14 and set a price target of $22.00. The company’s shares closed last Friday at $23.27, close to its 52-week low of $16.52.
According to TipRanks.com, Goodman is a 4-star analyst with an average return of
Currently, the analyst consensus on SAGE Therapeutics is a Hold with an average price target of $25.08, implying a -0.9% downside from current levels. In a report issued on February 14, Goldman Sachs also maintained a Hold rating on the stock with a $28.00 price target.
IQVIA Holdings (IQV)
In a report issued on February 14, Ann Hynes from Mizuho Securities maintained a Buy rating on IQVIA Holdings, with a price target of $242.00. The company’s shares closed last Friday at $238.60, close to its 52-week high of $243.82.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
IQVIA Holdings has an analyst consensus of Strong Buy, with a price target consensus of $265.75, a 10.1% upside from current levels. In a report issued on February 14, Bank of America Securities also maintained a Buy rating on the stock with a $255.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
